超越鼻整形中的软骨移植：鼻软骨再生的生物制药与生物材料策略

文献信息

中文摘要

自体鼻中隔、耳廓和肋软骨仍是结构性和美学鼻整形的参考材料，但每种来源都受限于可用量有限、供区并发症、几何形状多变以及变形、吸收或翻修的风险。因此，鼻软骨再生不仅仅是一个常规的组织工程问题：一个有临床价值的产品必须重建区域特异性的细胞外基质，在扩散受限的环境中存活，耐受缝合和周期性变形，保持鼻气道通畅，并在薄层软组织包膜下维持患者特异性的轮廓。本叙述性综述评估了满足这些要求的下一代生物制药和生物材料策略。来自人类鼻软骨细胞和工程化鼻构建体的直接证据与来自更广泛软骨再生的机制性证据相结合，并明确区分鼻、耳廓和关节数据。软骨生成蛋白和小分子，包括转化生长因子-β、骨形态发生蛋白、成纤维细胞生长因子18和kartogenin，可以启动基质形成程序，但需要空间和时间控制以避免纤维软骨、肥大或矿化。聚脱氧核糖核苷酸和聚核苷酸制剂具有合理的抗炎和基质支持作用，但证据主要仍来自体外或关节研究；目前没有直接临床证据支持仅通过注射实现结构性鼻软骨的再生。细胞外囊泡提供了无细胞信号平台，而扩增的鼻软骨细胞目前具有最强的组织特异性转化谱系。可注射的胶原、纤维蛋白、藻酸盐、透明质酸、壳聚糖、明胶-甲基丙烯酰基和脱细胞基质系统可以定位这些载荷，尽管生物学许可性往往与即时机械强度相冲突。三维生物打印和增强型混合构建体提供了患者特异性的几何形状，但临床转化需要经过验证的效价测定、缝合保持力、弯曲测试、原位安全性、符合良好生产规范的生产，以及对形状和气流的长期客观评估。最可信的近期应用是对现有移植物进行生物学增强、修复小的局限性缺损以及患者特异性的部分框架替换，而不是仅通过再生注射进行微创重塑。提出了一种分阶段门控的转化框架，以协调分子效价、材料性能、手术可用性、美学精度和持久的鼻功能。

英文摘要

Autologous septal, auricular, and costal cartilage remain the reference materials for structural and aesthetic rhinoplasty, yet each source is constrained by finite availability, donor-site morbidity, variable geometry, and the risks of warping, resorption, or revision. Nasal cartilage regeneration therefore represents more than a conventional tissue-engineering problem: a clinically useful product must recreate region-specific extracellular matrix, survive in a diffusion-limited environment, tolerate suturing and cyclic deformation, preserve the nasal airway, and maintain patient-specific contour under a thin soft-tissue envelope. This narrative review evaluates next-generation biopharmaceutical and biomaterial strategies for meeting those requirements. Direct evidence from human nasal chondrocytes and engineered nasal constructs is integrated with mechanistic evidence from broader cartilage regeneration, with explicit separation of nasal, auricular, and articular data. Chondrogenic proteins and small molecules, including transforming growth factor-beta, bone morphogenetic proteins, fibroblast growth factor 18, and kartogenin, can initiate matrix-forming programs but require spatial and temporal control to avoid fibrocartilage, hypertrophy, or mineralization. Polydeoxyribonucleotide and polynucleotide formulations have plausible anti-inflammatory and matrix-supportive actions, but evidence remains predominantly in vitro or articular; no direct clinical proof currently supports injection-only regeneration of structural nasal cartilage. Extracellular vesicles provide a cell-free signaling platform, whereas expanded nasal chondrocytes presently have the strongest tissue-specific translational lineage. Injectable collagen, fibrin, alginate, hyaluronic-acid, chitosan, gelatin-methacryloyl, and decellularized-matrix systems can localize these cargos, although biologic permissiveness often conflicts with immediate mechanical strength. Three-dimensional bioprinting and reinforced hybrid constructs offer patient-specific geometry, but clinical translation requires validated potency assays, suture retention, flexural testing, orthotopic safety, Good Manufacturing Practice-compatible production, and long-term objective assessment of shape and airflow. The most credible near-term applications are biologic enhancement of existing grafts, repair of small contained defects, and patient-specific partial-framework replacement rather than minimally invasive reshaping by regenerative injection alone. A stage-gated translational framework is proposed to align molecular potency, material performance, surgical usability, aesthetic precision, and durable nasal function.